Skip to content
10-Q

Quarterly Report

WEREWOLF THERAPEUTICS, INC. HOWL

0001785530-26-000012

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 48.6M sh
Shares Diluted Q1 2026 · Mar 31, 2026 49.39M sh
Shares Diluted Q1 2026 · Mar 31, 2025 44.83M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$10.6M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$18.95M
Long Term Debt Q1 2026 · Mar 31, 2026 $32.09M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $46.45M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $57.05M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $92.04M
Stockholders Equity Q1 2026 · Mar 31, 2026 $12.2M
Stockholders Equity Q1 2026 · Dec 31, 2025 $24.81M
Stockholders Equity Q1 2026 · Mar 31, 2025 $57.31M
Stockholders Equity Q1 2026 · Dec 31, 2024 $73.39M
Current Liabilities Q1 2026 · Mar 31, 2026 $38.52M
Current Liabilities Q1 2026 · Dec 31, 2025 $36.15M
Total Liabilities Q1 2026 · Mar 31, 2026 $45.82M
Total Liabilities Q1 2026 · Dec 31, 2025 $44.59M
Current Assets Q1 2026 · Mar 31, 2026 $48.73M
Current Assets Q1 2026 · Dec 31, 2025 $58.59M
Total Assets Q1 2026 · Mar 31, 2026 $58.02M
Total Assets Q1 2026 · Dec 31, 2025 $69.4M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.28
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.40
Eps Basic Q1 2026 · Mar 31, 2026 −$0.28
Eps Basic Q1 2026 · Mar 31, 2025 −$0.40
Sga Expense Q1 2026 · Mar 31, 2026 $5.09M
Sga Expense Q1 2026 · Mar 31, 2025 $4.87M
Rd Expense Q1 2026 · Mar 31, 2026 $8.18M
Rd Expense Q1 2026 · Mar 31, 2025 $13.12M
Net Income Q1 2026 · Mar 31, 2026 −$13.53M
Net Income Q1 2026 · Mar 31, 2025 −$18.09M
Operating Income Q1 2026 · Mar 31, 2026 −$13.27M
Operating Income Q1 2026 · Mar 31, 2025 −$17.99M